1385 West 8th Avenue
About Zymeworks Inc
Established in 2003 with offices in Vancouver, BC and Seattle, WA, Zymeworks is a fast-growing, clinical-stage biotechnology company dedicated to the research, development and commercialization of best-in-class therapeutic bispecific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. Zymeworks is proud to have active collaborations with Merck, Eli Lilly, Celgene, GlaxoSmithKline, Daiichi-Sankyo, Johnson & Johnson, Leo Pharma and BeiGene and is committed to making a meaningful difference in the lives of patients everywhere.
105 articles with Zymeworks Inc
Zymeworks Inc. announced that it will host a webcast and conference call to discuss progress on its 2019 corporate priorities, including clinical development plans for its lead therapeutic candidates as well as recently announced and established corporate partnerships.
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that GSK has expanded its 2016 licensing and collaboration agreement with Zymeworks for the research, development, and commercialization of bispecific antibodies across multiple disease areas.
5/16/2019Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more.
Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Therapeutics, Inc. (Iconic) non-exclusive rights to Zymeworks’ proprietary ZymeLink™ antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer.
Today reported financial results for the first quarter ended March 31, 2019.
Zymeworks Inc. announced it has expanded its leadership team with the hiring of three new vice presidents to support the Company’s expanded global clinical development: Mark Hollywood, Senior Vice President, Technical and Manufacturing Operations; Neil Josephson, M.D., Vice President, Clinical Research; and Bruce Hart, Ph.D., Vice President, Regulatory Affairs.
Zymeworks Inc. announced that management will present at the upcoming Bloom Burton & Co. Healthcare Investor Conference taking place April 30-May 1, 2019 in Toronto, Canada.
Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers
Zymeworks Inc. announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas.
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, reported financial results for the year ended December 31, 2018.
Zymeworks Reports Second Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration
- Lilly’s second immune-oncology candidate using Zymeworks’ novel Azymetric™ platform to start clinical trials - Zymeworks to receive milestone payment of US$8.0 million for this second IND submission - Lilly is one of eight pharma partners; INDs by others anticipated - Total value of remaining potential milestones for all Zymeworks’ partnerships exceeds US$7.6 billion
Zymeworks Inc. today reviewed its key 2018 accomplishments and outlined the Company’s priorities for 2019.
Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium
ZW49 combines Azymetric™ and ZymeLink™ technologies to broaden the therapeutic window of antibody-drug conjugates (ADCs)
Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium
ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types
Zymeworks Inc. today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England.
ProBioGen AG announced today that it has completed a cell line development project for one of Zymeworks Inc.’s bispecific antibody program which exceeded expectations.
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018. “
Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30th EORTC-NCI-AACR Symposium
Results from Phase 1 trial highlight ZW25’s single agent effect in HER2-driven cancers
The companies will collaborate on the discovery of novel monospecific antibodies to develop bispecific therapeutics targeting cytokine-receptor pathways with applications in dermatology, inflammation, and autoimmunity by leveraging Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms
Zymeworks Inc. and LEO Pharma A/S have entered into a licensing and research collaboration to discover and develop bispecific antibodies.
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will webcast its R&D Briefing from 9:00 a.m. to 12:00 p.m. Eastern Time on Thursday, October 11, 2018 in New York City.